Skip to contentHarwin Peter Evan — Zenas BioPharma, Inc. insider: 44 transactions · InsiderLensHarwin Peter Evan
- Director at Dianthus Therapeutics, Inc. /DE/ · on record since Sep 28, 2023
- 10% owner at Dianthus Therapeutics, Inc. /DE/ · on record since Sep 28, 2023
- Director at APOGEE ROBOTICS INC · on record since Jul 17, 2023
- 10% owner at Zenas BioPharma, Inc. · on record since Sep 12, 2024
- Director at Damora Therapeutics, Inc. · on record since Nov 17, 2025
- 10% owner at Damora Therapeutics, Inc. · on record since Nov 17, 2025
- Director at Zenas BioPharma, Inc. · on record since Apr 1, 2026
- Director at GLYCOMIMETICS INC · on record since Jun 3, 2026
- 10% owner at GLYCOMIMETICS INC · on record since Jun 3, 2026
- Director at NUVELO INC · on record since Jun 3, 2026
- 10% owner at NUVELO INC · on record since Jun 3, 2026
- Director at Cogent, Inc. · on record since Jun 11, 2026
- Director at Jade Biosciences, Inc. · on record since Jun 11, 2026
- 10% owner at Jade Biosciences, Inc. · on record since Jun 11, 2026
- 10% owner at Mirati Therapeutics, Inc. · on record since Jan 15, 2016
- Director at MED GEN INC · on record since Oct 29, 2020
- Director at Viridian Therapeutics, Inc.\DE · on record since Feb 8, 2021
- Director at Spyre Therapeutics, Inc. · on record since Jun 30, 2023
- 10% owner at Spyre Therapeutics, Inc. · on record since Jun 30, 2023
Insider trading activity of Harwin Peter Evan
- Transactions on record
- 44
- since Aug 31, 2020
- Open-market buys
- 4
- $29.7M
- Open-market sells
- 1
- $133.5M
- Companies traded
- 9
- last filing Jun 11, 2026
Figures computed from official regulatory filings — methodology.
Companies where Harwin Peter Evan has traded
- Cogent, Inc.7 tx · Jun 11, 2026
- APOGEE ROBOTICS INC10 tx · $133.5M · Jan 22, 2026
- GLYCOMIMETICS INC3 tx · $20M · Dec 8, 2025
- Zenas BioPharma, Inc.11 tx · $11.1M · Oct 9, 2025
- Jade Biosciences, Inc.1 tx · May 1, 2025
- Viridian Therapeutics, Inc.\DE5 tx · Jun 28, 2024
- Spyre Therapeutics, Inc.5 tx · $10M · May 16, 2024
- Dianthus Therapeutics, Inc. /DE/1 tx · $336.3K · Oct 3, 2023
- MED GEN INC1 tx · Oct 29, 2020
Track record of Harwin Peter Evan
Statistical track record
Free- Open-market buys
- 5
- Last buy
- Dec 4, 2025
Win rates and median returns are available with a free account (5 insiders/month).
Create a free account→Transaction history of Harwin Peter Evan
Co-insiders of Harwin Peter Evan
This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →
Morris ArleneCogent, Inc. +2
| Company | Filed | Type | Qty | Price | Value · USD | Src |
|---|
| Jun 11, 2026 | AwardD | 17,901 | 0.00 USD | $0 | SEC |
| Jan 22, 2026 | Sell | -1,750,000 | 76.30 USD | $133.5M | SEC |
| Dec 8, 2025 | Buy | 1,360,000 | 13.41 USD | $18.2M | SEC |
| Dec 8, 2025 | BuyD | 131,434 | 13.41 USD | $1.8M | SEC |
| Oct 9, 2025 | Buy | 316,219 | 19.00 USD | $6M | SEC |
| Jun 23, 2025 | AwardD | 9,023 | 0.00 USD | $0 | SEC |
| Jun 5, 2025 | AwardD | 44,700 | 0.00 USD | $0 | SEC |
| May 1, 2025 | AwardD | 23,017 | 0.00 USD | $0 | SEC |
| Sep 16, 2024 | Buy | 300,000 | 17.00 USD | $5.1M | SEC |
| Sep 16, 2024 | Other | 252,890 | — | — | SEC |
| Sep 16, 2024 | Other | 41,130 | — | — | SEC |
| Sep 16, 2024 | OtherD | -2,195,871 | — | — | SEC |
| Sep 16, 2024 | OtherD | -6,163,236 | — | — | SEC |
| Sep 16, 2024 | Other | 709,794 | — | — | SEC |
| Sep 16, 2024 | Other | 301,077 | — | — | SEC |
| Sep 16, 2024 | AwardD | 37,000 | 0.00 USD | $0 | SEC |
| Sep 16, 2024 | OtherD | -2,614,287 | — | — | SEC |
| Sep 16, 2024 | OtherD | -357,143 | — | — | SEC |
| Jun 28, 2024 | AwardD | 21,000 | 0.00 USD | $0 | SEC |
| Jun 13, 2024 | AwardD | 44,700 | 0.00 USD | $0 | SEC |
| Jun 7, 2024 | AwardD | 10,370 | 0.00 USD | $0 | SEC |
| Jun 7, 2024 | AwardD | 10,370 | 0.00 USD | $0 | SEC |
| May 16, 2024 | AwardD | 11,323 | 0.00 USD | $0 | SEC |
| May 16, 2024 | AwardD | 11,323 | 0.00 USD | $0 | SEC |
| Apr 25, 2024 | Exercise | 3,639,680 | 0.00 USD | $0 | SEC |